Skip to main navigation Skip to search Skip to main content

Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women

Research output: Contribution to journalArticlepeer-review

Abstract

Female sexual interest/arousal disorder (FSIAD) is a newly defined clinical diagnosis that appears in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). 1 The diagnosis was previously listed as hypoactive sexual desire disorder (HSDD) in DSM-4 and as inhibited sexual desire disorder in DSM-3. References to the condition prior to 2013 (and even afterward), including research studies, often refer to the condition as HSDD.

Original languageAmerican English
JournalP&T (Pharmacy & Therapeutics)
Volume42
Issue number4
StatePublished - Apr 1 2017

Keywords

  • arousal
  • females
  • hypoactive sexual desire disorder (HSDD)
  • menopause
  • pre-menopause
  • sexual interest

Disciplines

  • Medicine and Health Sciences
  • Pharmacy and Pharmaceutical Sciences

Fingerprint

Dive into the research topics of 'Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women'. Together they form a unique fingerprint.

Cite this